UroGen Pharma (URGN) Non-Current Debt (2022 - 2026)

UroGen Pharma (URGN) has reported Non-Current Debt for 5 consecutive years, with $189.5 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Debt rose 55.22% year-over-year to $189.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $189.5 million (up 55.22% YoY) and the FY2025 annual result came in at $122.2 million, changed 0.39% from the prior year.
• Non-Current Debt climbed to $189.5 million in Q1 2026 per URGN's latest filing, from $122.2 million in the prior quarter.
• Over the last five years, Non-Current Debt for URGN reached as high as $189.5 million in Q1 2026 and fell as low as $70.8 million in Q1 2022.
• A 5-year average of $107.2 million and a median of $98.5 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2024 — Non-Current Debt dropped 0.49% — and 2026, when it soared 55.22%.
• Year by year, Non-Current Debt stood at $97.5 million in 2022, then gained by 1.04% to $98.6 million in 2023, then grew by 23.52% to $121.7 million in 2024, then climbed by 0.39% to $122.2 million in 2025, then surged by 55.09% to $189.5 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $189.5 million, $122.2 million, and $122.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.